Free tool
Oncology stocks
We cover 7 companies grouped under the Oncology theme. The median market value in the group is $11.16B. Across the group, the median move over the past trading day is +0.14%. Price change over the past year runs from −14.6% to +109.6% across the middle 80 percent of the group, with a median of +20.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.49% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| 0M2N.L | Orion Oyj | $11.16B | Large cap | +20.48% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $707.84M | Small cap | +9.60% |
| 0LOV.L | Verastem, Inc. | $470.33M | Small cap | −19.93% |
| 0XOD.L | UroGen Pharma Ltd. | $347.24M | Small cap | +136.88% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.